Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Crolll (Germany) | Researchclopedia

Back to institutions

Crolll (Germany)

Nurembergcompany

20

Works

36

Citations

2

h-index

Top Research Topics

Cancer Immunotherapy and Biomarkers Pancreatic and Hepatic Oncology Research Immunotherapy and Immune Responses

Top Researchers

Toni Fetzer Crolll (Germany)

25 works344 citationsh-index: 10

Recent Research

Predictive criteria for overall survival and treatment duration of 2nd-line chemotherapy in patients with advanced pancreatic adenocarcinoma (AIO-PAK-0216)

Manfred P. Lutz,N. Ansorge,et al.

20250 citations

Esophageal Cancer Research and Treatment

Lung Cancer Treatments and Mutations

Cancer Genomics and Diagnostics

Genomics and Phylogenetic Studies

Hepatocellular Carcinoma Treatment and Prognosis

Lung Cancer Diagnosis and Treatment

Indoor and Outdoor Localization Technologies

Pharmacogenetics and Drug Metabolism

Renal cell carcinoma treatment

Markos Schulte Crolll (Germany)

5 works64 citationsh-index: 2

Tobias Leidig Crolll (Germany)

7 works32 citationsh-index: 2

Sabine Höfling Crolll (Germany)

2 works2 citationsh-index: 1

M. Schulte Crolll (Germany)

3 works1 citationsh-index: 1

S. Hoefling Crolll (Germany)

5 works1 citationsh-index: 1

Interpolation of Position Estimates for Radio Fingerprinting using Gaussian Process Regression

Michael Werner,Markus Bullmann,et al.

20250 citations

2251P Immune features of the tumor microenvironment are mirrored in PBMCs and predict second-line outcome in advanced pancreatic cancer: Insights from the PREDICT trial

A. Lahusen,Manfred P. Lutz,et al.

20250 citations

An immune responsive tumor microenvironment imprints into PBMCs and predicts outcome in advanced pancreatic cancer: lessons from the PREDICT trial

Anton Lahusen,Manfred P. Lutz,et al.

20252 citations

Second-line therapy with Nal-IRI/5-FU/FA after failure of gemcitabine/nab-paclitaxel in advanced pancreatic cancer (PC): Predictive role of 1st-line therapy (PREDICT) and impact of quality of life (QoL).

Meinolf Karthaus,Jérôme Schwingel,et al.

20250 citations

Functional status and quality of life in older patients with advanced esophageal squamous cell cancer receiving second-line nivolumab ± ipilimumab therapy: A post hoc analysis of the phase 2, multicenter RAMONA study

Moying Li,Nadja M. Meindl‐Beinker,et al.

20242 citations